TIRZ / IGF-1 LR3Check methods and identity
Why two compounds given together and a single formulation are separate questions
3 numbered sourcesSource years 2023–2026
Peptides are short amino-acid chains connected by peptide bonds. Their sequences and chemical forms help determine how they interact with receptors and other molecules. Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified version of the growth-factor protein IGF-1. Studies registered for tirzepatide with a different molecule illustrate why the preparation is part of what researchers have to define. [1, 2, 3]
An early trial registry describes bimagrumab, an investigational antibody, studied with tirzepatide in healthy participants. The researchers included comparisons involving separate coadministration and a combined formulation. A bioavailability study asks how much of the studied material reaches the bloodstream and how that exposure changes over time. Comparing two forms can help determine whether putting them in one formulation changes exposure under the tested conditions. [1]
A separate phase 2 registry describes a trial of bimagrumab and tirzepatide alone or together in adults with obesity or overweight without type 2 diabetes. That comparison is designed to study efficacy and safety in a defined clinical population. Its stated question differs from the early study’s question about exposure. Both records listed no posted results at the November 8, 2026 cutoff. [1, 2]
The trials identify bimagrumab as the added agent. IGF-1 LR3 is a different material and was not part of either design. The distinction matters for an entry that simply lists two names. An experimental result belongs to the actual ingredients, preparation and outcome that were studied. A registry for a different antibody pairing can illustrate how scientists distinguish these questions without providing any exposure or outcome estimate for tirzepatide with IGF-1 LR3. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Eli Lilly and Company. A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants. ClinicalTrials.gov (publication 2025-03-24, record updated 2025-10-09). (opens in a new tab)
clinicaltrials.gov↩ Back to text
- 2.Eli Lilly and Company. A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes. ClinicalTrials.gov (publication 2024-10-16, record updated 2026-05-26). (opens in a new tab)
clinicaltrials.gov↩ Back to text
